Articles

Siteman

Cell-based immunotherapy shows promise against melanoma

Source: SITEMAN Cancer Center, Julia Evangelou Strait, June 2021.

Wugen: deploying memory NK cells against cancer

Source: BIOCENTURY Wugen: deploying memory NK cells against cancer AND TURNING ALLOGENEIC CAR T CELLS AGAINST T CELL MALIGNANCIES BY LAUREN MARTZ, …

The Development of Natural Killer Cells for Solid Tumor Treatment

Currently approved cellular therapies have been shown to effectively treat B-cell cancers, but there remains a significant unmet need for treating other cancers, including solid tumors.

BioWorld: Alpha Biopharma lands deal for Wugen’s memory NK and CAR T cells for Asia

BioWorld, David Ho, March 2021.

The Promise of Natural Killer Cells

Technology Networks, Ryan Sullivan, Wugen, March 2021

St. Louis biotech startup Wugen inks manufacturing deal, hires C-suite exec

St. Louis Business Journal, Nathan Rubbelke, March 2021

St. Louis biotech startup Wugen inks licensing deal, hires new C-suite exec

St. Louis Business Journal, Nathan Rubbelke, February 2021

Wugen Ramps Up Off-the-Shelf Gene Therapies to Fight Cancer

Biospace, Kate Goodwin, January 2021

Latest News

Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007

— Data Support Start of First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell …

Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma

— First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy to Begin in …

Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cell Therapy

ST. LOUIS, MO and SAN DIEGO, CA, Nov. 12, 2024 – Wugen, Inc., a clinical-stage U.S. …

ST. LOUIS

4260 Forest Park Ave
Suite 100
St. Louis, MO 63108
(636) 385-5306

SAN DIEGO

9880 Campus Point Dr
Suite 430
San Diego, CA 92121

SOCIAL

Copyright © 2024 Wugen. All Rights Reserved.

Privacy Notice
a COGNEO design